drugset / Trial / NCT03417739
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Timeline
- Start
- 2018-03-26
- Primary completion
- 2020-05-05
- Completion
- 2025-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulixertinib | Small molecule | 600 mg | Oral |